View
64
Download
1
Category
Preview:
Citation preview
1. Therapeutic promise of the targets and proposed
mechanisms of action just presented?
Other promising approaches not presented?
2. From a clinical perspective, where is the unmet need in DME and wet AMD? Neuroprotection, anti-fibrosis, anti-permeability,
anti-angiogenesis, other?
3. As these and other phase 2/3 trials approach proof of concept, what will represent a clinically meaningful visual improvement above and beyond anti-VEGF-A therapy? A mean improvement
of 4-5 letters? Injection burden? Other?
4. Assuming approval of one or more of the discussed drugs as add-on or adjunctive therapy,
how will this impact patient flow and injection practices?
What will retina practices look like in 2020?
Recommended